acute myeloid leukemia
Conditions
Interventions
Eexperimental group:Azacytidine plus low dose venetoclax
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged at least 60 years; 2. Patients diagnosed as AML (not APL); 3. Previously untreated; 4. No uncontrolled current infection (new infection, broad spectrum antibiotics, body temperature greater than 38? within 72 hours, excluding other non-infectious factors); 5. The patients themselves or their family members are willing to participate in the study and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cardiopulmonary or other important organ dysfunction; 2. Patients who cannot comprehend or follow the plan with a brain disorder or serious mental diseases; 3. Patients combined with other malignant tumors; 4. Patients with CNSL involvement; 5. Patients whose necessary treatment plan and follow-up observation cannot be guaranteed.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission;Complete remission with incomplete blood count recovery;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to response;Duration of response;Rates of death;Relapse rate; | — |
Countries
China
Contacts
Public ContactLiu Hui
Beijing Hospital
Outcome results
None listed